Mesa Laboratories, Inc. (NASDAQ:MLAB) Director H Stuart Campbell sold 608 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $134.08, for a total transaction of $81,520.64. Following the sale, the director now directly owns 45,368 shares of the company’s stock, valued at approximately $6,082,941.44. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

H Stuart Campbell also recently made the following trade(s):

  • On Wednesday, August 9th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $137.61, for a total transaction of $137,610.00.
  • On Thursday, August 10th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $136.58, for a total transaction of $136,580.00.
  • On Friday, August 4th, H Stuart Campbell sold 1,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $143.09, for a total transaction of $143,090.00.
  • On Thursday, August 3rd, H Stuart Campbell sold 2,000 shares of Mesa Laboratories stock. The shares were sold at an average price of $143.37, for a total transaction of $286,740.00.

Mesa Laboratories, Inc. (NASDAQ:MLAB) traded down 1.43% during mid-day trading on Tuesday, reaching $131.93. 4,189 shares of the company’s stock were exchanged. Mesa Laboratories, Inc. has a one year low of $102.14 and a one year high of $169.80. The stock has a 50-day moving average of $143.67 and a 200-day moving average of $136.35. The stock has a market cap of $495.79 million, a price-to-earnings ratio of 47.42 and a beta of 0.46.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing the Zacks’ consensus estimate of $0.56 by $0.17. The company had revenue of $22.67 million during the quarter, compared to analysts’ expectations of $22.90 million. Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. On average, equities research analysts anticipate that Mesa Laboratories, Inc. will post $2.72 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Shareholders of record on Thursday, August 31st will be paid a $0.16 dividend. The ex-dividend date is Tuesday, August 29th. This represents a $0.64 dividend on an annualized basis and a yield of 0.48%. Mesa Laboratories’s dividend payout ratio (DPR) is currently 22.94%.

WARNING: “H Stuart Campbell Sells 608 Shares of Mesa Laboratories, Inc. (MLAB) Stock” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/15/h-stuart-campbell-sells-608-shares-of-mesa-laboratories-inc-mlab-stock.html.

MLAB has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 target price for the company in a research report on Tuesday, June 13th. BidaskClub downgraded shares of Mesa Laboratories from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Finally, TheStreet downgraded shares of Mesa Laboratories from a “b” rating to a “c+” rating in a research report on Monday, July 31st.

Institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC bought a new position in shares of Mesa Laboratories during the second quarter worth approximately $221,000. Strs Ohio boosted its position in shares of Mesa Laboratories by 5.6% in the second quarter. Strs Ohio now owns 1,900 shares of the medical instruments supplier’s stock worth $272,000 after buying an additional 100 shares during the period. BT Investment Management Ltd bought a new position in shares of Mesa Laboratories during the second quarter worth approximately $277,000. Spark Investment Management LLC bought a new position in shares of Mesa Laboratories during the second quarter worth approximately $300,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Mesa Laboratories by 7.1% in the second quarter. The Manufacturers Life Insurance Company now owns 2,564 shares of the medical instruments supplier’s stock worth $367,000 after buying an additional 169 shares during the period. 67.11% of the stock is currently owned by institutional investors and hedge funds.

About Mesa Laboratories

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Insider Buying and Selling by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.